# US 2021/0261646 A1 · Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261646 A1
- Document ID: US20210261646A1
- Status: Published application
- Kind: A1
- Application number: 17/257,469
- Filed: 2019-07-02
- Published: 2021-08-26
- Earliest claimed: 2018-07-03
- Assignees: SOTIO a.s.
- Applicants: Sotio, LLC
- Inventors: Kathleen MCGINNESS; Seth ETTENBERG; Luke BARRON; Michael FRAY; Charles WILSON; Gregory Motz
- Web page: https://patentgrep.com/patent/US20210261646A1

## CPC

- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4256: {Tumor associated carbohydrates}
- A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- C07K 16/303: {Liver or Pancreas}
- C12N 5/0636: {T lymphocytes}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/53: Liver
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2502/30: tumour cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are genetically engineered immune cells, which express one or more glucose importation polypeptides and optionally a chimeric receptor polypeptide, for example, an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide. Also disclosed herein are uses of such genetically engineered immune cells for inhibiting cells expressing a target antigen in a subject in need of the treatment, either taken alone or in combination with an Fc-comprising agent (e.g., an antibody) that binds the target antigen.

## Claims

### Claim 1

A genetically engineered immune cell, wherein the immune cell has an improved glucose uptake activity as relative to a wild-type immune cell of the same type.

### Claim 2 (depends on 1)

The immune cell of claim 1, which expresses or overly expresses:
(i) a glucose importation polypeptide.

### Claim 3 (depends on 2)

The immune cell of claim 2, wherein the glucose importation polypeptide is a glucose transporter (GLUT) or a sodium-glucose cotransporter (SGLT).

### Claim 4 (depends on 2)

The immune cell of claim 2, wherein the glucose importation polypeptide is selected from the group consisting of: GLUT1, GLUT3, GLUT1 S226D, SGLT1, SGLT2, GLUT8, GLUT8 L12A L13A, GLUT11, GLUT7, and GLUT4.

### Claim 5 (depends on 1)

The immune cell of claim 1, which further expresses:
(ii) a chimeric receptor polypeptide; wherein the chimeric receptor polypeptide comprises:
(a) an extracellular target binding domain;
(b) a transmembrane domain; and
(c) a cytoplasmic signaling domain.

### Claim 6 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide is an antibody-coupled T cell receptor (ACTR) polypeptide, in which (a) is an extracellular Fc binding domain.

### Claim 7 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide is a chimeric antigen receptor (CAR) polypeptide, in which (a) is an extracellular antigen binding domain.

### Claim 8 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide further comprises at least one co-stimulatory signaling domain.

### Claim 9 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide, which optionally is a ACTR polypeptide, is free of co-stimulatory signaling domains.

### Claim 10 (depends on 5)

The immune cell of claim 5, wherein the cytoplasmic signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 11 (depends on 5)

The immune cell of claim 5, wherein the cytoplasmic signaling domain (c) is located at the C-terminus of the chimeric receptor polypeptide.

### Claim 12 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide further comprises a hinge domain, which is located at the C-terminus of (a) and the N-terminus of (b).

### Claim 13 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide further comprises a signal peptide at its N-terminus.

### Claim 14 (depends on 6)

The immune cell of claim 6, wherein the Fc binding domain of (a) is selected from the group consisting of:
(A) an extracellular ligand-binding domain of an Fc-receptor,
(B) an antibody fragment that binds the Fc portion of an immunoglobulin,
(C) a naturally-occurring protein that binds the Fc portion of an immunoglobulin or an Fc-binding fragment thereof, and
(D) a synthetic polypeptide that binds the Fc portion of an immunoglobulin.

### Claim 15 (depends on 14)

The immune cell of claim 14, wherein the Fc binding domain is (A), which is an extracellular ligand-binding domain of an Fc-gamma receptor, an Fc-alpha receptor, or an Fc-epsilon receptor.

### Claim 16 (depends on 15)

The immune cell of claim 15, wherein the Fc binding domain is an extracellular ligand-binding domain of CD16A, CD32A, or CD64A.

### Claim 17 (depends on 16)

The immune cell of claim 16, wherein the Fc binding domain is an extracellular ligand-binding domain of F158 CD16A or V158 CD16A.

### Claim 18 (depends on 14)

The immune cell of claim 14, wherein the Fc binding domain is (B), which is a single chain variable fragment (ScFv), a domain antibody, or a nanobody.

### Claim 19 (depends on 14)

The immune cell of claim 14, wherein the Fc binding domain is (C), which is Protein A or Protein G, or an Fc-binding fragment thereof.

### Claim 20 (depends on 14)

The immune cell of claim 14, wherein the Fc binding domain is (D), which is a Kunitz peptide, a SMIP, an avimer, an affibody, a DARPin, or an anticalin.

### Claim 21 (depends on 5)

The immune cell of claim 5, wherein the transmembrane domain of (b) is of a single-pass membrane protein.

### Claim 22 (depends on 7)

The immune cell of claim 7, wherein the extracellular antigen binding domain of (a) is a single chain antibody fragment that binds to a tumor antigen, a pathogenic antigen, or an immune cell specific to an autoantigen.

### Claim 23 (depends on 22)

The immune cell of claim 22, wherein the tumor antigen is associated with a hematologic tumor.

### Claim 24 (depends on 23)

The immune cell of claim 23, wherein the tumor antigen is selected from the group consisting of CD19, CD20, CD22, Kappa-chain, CD30, CD123, CD33, LeY, CD138, CD5, BCMA, CD7, CD40, and IL-1RAP.

### Claim 25 (depends on 23)

The immune cell of claim 23, wherein the tumor antigen is associated with a solid tumor.

### Claim 26 (depends on 25)

The immune cell of claim 25, wherein the tumor antigen is selected from the group consisting of GD2, GPC3, FOLR, HER2, EphA2, EFGRVIII, IL13RA2, VEGFR2, ROR1, NKG2D, EpCAM, CEA, Mesothelin, MUC1, CLDN18.2, CD171, CD133, PSCA, cMET, EGFR, PSMA, FAP, CD70, MUC16, L1-CAM, and CAIX.

### Claim 27 (depends on 22)

The immune cell of claim 22, wherein the pathogenic antigen is a bacterial antigen, a viral antigen, or a fungal antigen.

### Claim 28 (depends on 5)

The immune cell of claim 5, wherein the transmembrane domain of (b) is of a single-pass membrane protein.

### Claim 29 (depends on 28)

The immune cell of claim 28, wherein the transmembrane domain is of a membrane protein selected from the group consisting of CD8α, CD8β, 4-1BB, CD28, CD34, CD4, FcεRIγ, CD16A, OX40, CD3ζ, CD3ε, CD3γ, CD3δ, TCRα, CD32, CD64, VEGFR2, FAS, and FGFR2B.

### Claim 30 (depends on 5)

The immune cell of claim 5, wherein the transmembrane domain of (b) is a non-naturally occurring hydrophobic protein segment.

### Claim 31 (depends on 5)

The immune cell of claim 5, wherein the at least one co-stimulatory signaling domain is of a co-stimulatory molecule selected from the group consisting of 4-1BB, CD28, CD28LL→GG variant, OX40, ICOS, CD27, GITR, ICOS, HVEM, TIM1, LFA1, and CD2.

### Claim 32 (depends on 31)

The immune cell of claim 31, wherein the at least one co-stimulatory signaling domains is a CD28 co-stimulatory signaling domain or a 4-1BB co-stimulatory signaling domain.

### Claim 33 (depends on 5)

The immune cell of claim 5, wherein the ACTR polypeptide comprises two co-stimulatory signaling domains.

### Claim 34 (depends on 33)

The immune cell of claim 33, wherein the two co-stimulatory domains are:
(i) CD28 and 4-1BB; or
(ii) CD28LL→GG variant and 4-1BB.

### Claim 35 (depends on 33)

The immune cell of claim 33, wherein one of the co-stimulatory signaling domains is a CD28 co-stimulatory signaling domain; and wherein the other co-stimulatory domain is selected from the group consisting of a 4-1BB co-stimulatory signaling domain, an OX40 co-stimulatory signaling domain, a CD27 co-stimulatory signaling domain, and an ICOS co-stimulatory signaling domain.

### Claim 36 (depends on 5)

The immune cell of claim 5, wherein the cytoplasmic signaling domain of (c) is a cytoplasmic domain of CD3ζ or FcεR1γ.

### Claim 37 (depends on 12)

The immune cell of claim 12, wherein the hinge domain is 1 to 60 amino acids in length.

### Claim 38 (depends on 12)

The immune cell of claim 12, wherein the hinge domain is of CD28, CD16A, CD8α, or IgG.

### Claim 39 (depends on 12)

The immune cell of claim 12, wherein the hinge domain is a non-naturally occurring peptide.

### Claim 40 (depends on 39)

The immune cell of claim 39, wherein the hinge domain is an extended recombinant polypeptide (XTEN) or a (Gly4Ser)n polypeptide, in which n is an integer of 3-12, inclusive.

### Claim 41 (depends on 5)

The immune cell of claim 5, wherein the chimeric receptor polypeptide is free of any hinge domain.

### Claim 42 (depends on 41)

The immune cell of claim 41, wherein the chimeric receptor polypeptide is an ACTR polypeptide, which is free of a hinge domain from any non-CD16A receptor.

### Claim 43 (depends on 6)

The immune cell of claim 6, wherein the ACTR polypeptide comprises (i) a CD28 co-stimulatory domain; and (ii) a CD28 transmembrane domain, a CD28 hinge domain, or a combination thereof.

### Claim 44 (depends on 6)

The immune cell of claim 6, wherein the ACTR polypeptide comprises components (a)-(e) as shown in Table 3.

### Claim 45 (depends on 6)

The immune cell of claim 6, wherein the ACTR polypeptide comprises the amino acid sequence selected from SEQ ID NOs: 1-80.

### Claim 46 (depends on 7)

The immune cell of claim 7, wherein the chimeric receptor polypeptide is a CAR polypeptide, which comprises (i) a CD28 co-stimulatory domain; in combination with a CD28 transmembrane domain, a CD28 hinge domain, or a combination thereof, or (ii) a 4-1BB co-stimulatory domain in combination with a CD8 transmembrane domain, a CD8 hinge domain, or a combination thereof.

### Claim 47 (depends on 7)

The immune cell of claim 7, wherein the CAR polypeptide comprises the amino acid sequence of SEQ ID NOs: 104 or 105.

### Claim 48 (depends on 1)

The immune cell of claim 1, wherein the immune cell is a natural killer cell, macrophage, neutrophil, eosinophil, or T cell.

### Claim 49 (depends on 48)

The immune cell of claim 48, wherein the immune cell is a T cell in which the expression of an endogenous T cell receptor, an endogenous major histocompatibility complex, an endogenous beta-2-microglobulin, or a combination thereof has been inhibited or eliminated.

### Claim 50 (depends on 1)

The immune cell of claim 1, wherein the immune cell is derived from peripheral blood mononuclear cells (PBMC), hematopoietic stem cells (HSCs), or inducible pluripotent stem cells (iPSCs).

### Claim 51 (depends on 1)

The immune cell of claim 1, wherein the immune cell comprises a nucleic acid or nucleic acid set, which collectively comprises:
(A) a first nucleotide sequence encoding the glucose importation polypeptide; and optionally
(B) a second nucleotide sequence encoding the chimeric receptor polypeptide.

### Claim 52 (depends on 51)

The immune cell of claim 51, wherein the nucleic acid or the nucleic acid set is an RNA molecule or a set of RNA molecules.

### Claim 53 (depends on 51)

The immune cell of claim 51, wherein the immune cell comprises the nucleic acid, which comprises both the first nucleotide sequence and the second nucleotide sequence.

### Claim 54 (depends on 53)

The immune cell of claim 53, wherein the nucleic acid further comprises a third nucleotide sequence located between the first nucleotide sequence and the second nucleotide sequence, wherein the third nucleotide sequence encodes a ribosomal skipping site, an internal ribosome entry site (IRES), or a second promoter.

### Claim 55 (depends on 54)

The immune cell of claim 54, wherein the third nucleotide sequence encodes a ribosomal skipping site, which is a P2A peptide.

### Claim 56 (depends on 51)

The immune cell of claim 51, wherein the nucleic acid or the nucleic acid set is comprised within a vector or a set of vectors.

### Claim 57 (depends on 56)

The immune cell of claim 56, wherein the vector or set of vectors is an expression vector or a set of expression vectors.

### Claim 58 (depends on 56, 57)

The immune cell of claim 56 or 57, wherein the vector or set of vectors comprises one or more viral vectors.

### Claim 59 (depends on 58)

The immune cell of claim 58, wherein the one or more viral vectors is a lentiviral vector or retroviral vector.

### Claim 60 (depends on 1)

A pharmaceutical composition, comprising an immune cell of claim 1, and a pharmaceutically acceptable carrier.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the immune cell further expresses a chimeric receptor polypeptide, which is an ACTR polypeptide, and the composition further comprises an Fc-containing therapeutic agent.

### Claim 62 (depends on 61)

The pharmaceutical composition of claim 61, wherein the Fc-containing therapeutic agent is a therapeutic antibody or an Fc fusion protein.

### Claim 63 (depends on 61)

The pharmaceutical composition of claim 61, wherein the Fc-containing therapeutic agent binds to a target antigen, which optionally is a tumor antigen, a pathogenic antigen, or an immune cell specific to an autoantigen.

### Claim 64 (depends on 63)

The pharmaceutical composition of claim 63, wherein the pathogenic antigen is a bacterial antigen, a viral antigen, or a fungal antigen.

### Claim 65 (depends on 64)

The pharmaceutical composition of claim 64, wherein the Fc-containing therapeutic agent is a therapeutic antibody selected from the group consisting of Adalimumab, Ado-Trastuzumab emtansine, Alemtuzumab, Basiliximab, Bevacizumab, Belimumab, Brentuximab, Canakinumab, Cetuximab, Certolizumab, Daclizumab, Denosumab, Dinutuximab, Eculizumab, Efalizumab, Epratuzumab, Gemtuzumab, Golimumab, hu14.18K322A, Ibritumomab, Infliximab, Ipilimumab, Labetuzumab, Muromonab, Natalizumab, Obinutuzumab, Ofatumumab, Omalizumab, Palivizumab, Panitumumab, Pertuzumab, Ramucirumab, Ranibizumab, Rituximab, Tocilizumab, Trastuzumab, Tositumomab, Ustekinumab, Mogamulizumab, and Vedolizumab.

### Claim 66 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A kit, comprising:
a first pharmaceutical composition that comprises an immune cell of any one of claims 5-59, which expresses an ACTR polypeptide, and a pharmaceutically acceptable carrier; and
a second pharmaceutical composition that comprises an Fc-containing therapeutic agent and a pharmaceutically acceptable carrier.

### Claim 67 (depends on 66)

The kit of claim 66, wherein the Fc-containing therapeutic agent is an Fc fusion protein or a therapeutic antibody.

### Claim 68 (depends on 66)

The kit of claim 66, wherein the Fc-containing therapeutic agent binds to a target antigen, which optionally is a tumor antigen, a pathogenic antigen, or an immune cell specific to an autoantigen.

### Claim 69 (depends on 67)

The kit of claim 67, wherein the therapeutic antibody is selected from the group consisting of Adalimumab, Ado-Trastuzumab emtansine, Alemtuzumab, Basiliximab, Bevacizumab, Belimumab, Brentuximab, Canakinumab, Cetuximab, Certolizumab, Daclizumab, Denosumab, Dinutuximab, Eculizumab, Efalizumab, Epratuzumab, Gemtuzumab, Golimumab, hu14.18K322A, Ibritumomab, Infliximab, Ipilimumab, Labetuzumab, Muromonab, Natalizumab, Obinutuzumab, Ofatumumab, Omalizumab, Palivizumab, Panitumumab, Pertuzumab, Ramucirumab, Ranibizumab, Rituximab, Tocilizumab, Trastuzumab, Tositumomab, Ustekinumab, Mogamulizumab, and Vedolizumab.

### Claim 70 (depends on 5)

A method for inhibiting cells expressing a target antigen in a subject, the method comprising administering to a subject in need thereof a population of the immune cells set forth in claim 5.

### Claim 71 (depends on 70)

The method of claim 70, wherein the immune cells expresses an ACTR polypeptide, and wherein the subject has been treated or is being treating with an Fc-containing therapeutic agent specific to the target antigen.

### Claim 72 (depends on 70)

The method of claim 70, wherein the immune cell expresses a CAR polypeptide that comprises an extracellular antigen binding domain specific to the target antigen.

### Claim 73 (depends on 71)

The method of claim 71, wherein the target antigen is a tumor antigen, a pathogenic antigen, or an immune cell specific to an autoantigen.

### Claim 74 (depends on 73)

The method of claim 73, wherein the pathogenic antigen is a bacterial antigen, a viral antigen, or a fungal antigen.

### Claim 75 (depends on 70)

The method of claim 70, wherein at least some of the cells expressing the target antigen are located in a low-glucose environment.

### Claim 76 (depends on 70)

The method of claim 70, wherein the immune cells are autologous.

### Claim 77 (depends on 70)

The method of claim 70, wherein the immune cells are allogeneic.

### Claim 78 (depends on 70)

The method of claim 70, wherein the immune cells are activated, expanded, or both ex vivo.

### Claim 79 (depends on 70)

The method of claim 70, wherein the Fc-containing therapeutic agent is a therapeutic antibody or an Fc fusion protein.

### Claim 80 (depends on 79)

The method of claim 79, wherein the Fc-containing therapeutic agent is a therapeutic antibody selected from the group consisting of Adalimumab, Ado-Trastuzumab emtansine, Alemtuzumab, Basiliximab, Bevacizumab, Belimumab, Brentuximab, Canakinumab, Cetuximab, Certolizumab, Daclizumab, Denosumab, Dinutuximab, Eculizumab, Efalizumab, Epratuzumab, Gemtuzumab, Golimumab, hu14.18K322A, Ibritumomab, Infliximab, Ipilimumab, Labetuzumab, Muromonab, Natalizumab, Obinutuzumab, Ofatumumab, Obinutuzumab, Omalizumab, Palivizumab, Panitumumab, Pertuzumab, Ramucirumab, Ranibizumab, Rituximab, Tocilizumab, Tositumomab, Trastuzumab, Ustekinumab, and Vedolizumab.

### Claim 81 (depends on 70)

The method of claim 70, wherein the subject is a human patient suffering from a cancer and the target antigen is a tumor antigen.

### Claim 82 (depends on 81)

The method of claim 81, wherein the cancer is selected from the group consisting of carcinoma, lymphoma, sarcoma, blastoma, and leukemia.

### Claim 83 (depends on 81)

The method of claim 81, wherein the cancer is selected from the group consisting of a cancer of B-cell origin, breast cancer, gastric cancer, neuroblastoma, osteosarcoma, lung cancer, skin cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, rhabdomyosarcoma, leukemia, mesothelioma, pancreatic cancer, head and neck cancer, retinoblastoma, glioma, glioblastoma, liver cancer, and thyroid cancer.

### Claim 84 (depends on 83)

The method of claim 83, wherein the cancer of B-cell origin is selected from the group consisting of B-lineage acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, and B-cell non-Hodgkin's lymphoma.

### Claim 85 (depends on 70)

The method of claim 70, wherein the immune cells comprise T cells, which are activated in the presence of one or more of anti-CD3 antibody, anti-CD28 antibody, IL-2, phytohemoagglutinin, and an engineered artificial stimulatory cell or particle.

### Claim 86 (depends on 70)

The method of claim 70, wherein the immune cells comprise natural killer cells, which are activated in the presence of one or more of 4-1BB ligand, anti-4-1BB antibody, IL-15, anti-IL-15 receptor antibody, IL-2, IL-12, IL-21 and K562 cells, and an engineered artificial stimulatory cell or particle.

### Claim 87

A nucleic acid or nucleic acid set, which collectively comprises:
(A) a first nucleotide sequence encoding a chimeric receptor polypeptide comprising: (a) an extracellular target binding domain; (b) a transmembrane domain; and (c) a cytoplasmic signaling domain; and
(B) a second nucleotide sequence encoding a glucose importation polypeptide.

### Claim 88 (depends on 87)

The nucleic acid or nucleic acid set of claim 87, wherein the nucleic acid or the nucleic acid set is an RNA molecule or a set of RNA molecules.

### Claim 89 (depends on 87)

The nucleic acid or nucleic acid set of claim 87, wherein the nucleic acid comprises both the first nucleotide sequence and the second nucleotide sequence, and wherein the nucleic acid further comprises a third nucleotide sequence located between the first nucleotide sequence and the second nucleotide sequence, the third nucleotide sequence encoding a ribosomal skipping site, an internal ribosome entry site (IRES), or a second promoter.

### Claim 90 (depends on 89)

The nucleic acid or nucleic acid set of claim 89, wherein the ribosomal skipping site is a P2A peptide.

### Claim 91 (depends on 87)

The nucleic acid or nucleic acid set of claim 87, wherein the nucleic acid or the nucleic acid set is comprised within a vector or a set of vectors.

### Claim 92 (depends on 91)

The nucleic acid or nucleic acid set of claim 91, wherein the vector or set of vectors is an expression vector or a set of expression vectors.

### Claim 93 (depends on 91)

The nucleic acid or nucleic acid set of claim 91, wherein the vector or set of vectors comprises one or more viral vectors.

### Claim 94 (depends on 93)

The nucleic acid or nucleic acid set of claim 93, wherein the one or more viral vectors is a retroviral vector, which optionally is a lentiviral vector or a gamma retroviral vector.
